166887-84-9

Basic information

• Product Name: 2-(broMoMethyl)-5-nitrothiophene
• Synonyms: 2-(broMoMethyl)-5-nitrothiophene
• CAS NO: 166887-84-9
• Molecular Formula: C₅H₄BrNO₂S
• Molecular Weight: 222.05976
• Mol File: 166887-84-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 312.0±27.0 °C(Predicted)
• Appearance: /
• Density: 1.846±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2-(broMoMethyl)-5-nitrothiophene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(broMoMethyl)-5-nitrothiophene(166887-84-9)
• EPA Substance Registry System: 2-(broMoMethyl)-5-nitrothiophene(166887-84-9)

Safety Data

• Hazardous Substances Data: 166887-84-9(Hazardous Substances Data)

Usage

General Description

2-(bromomethyl)-5-nitrothiophene is a chemical compound that contains a thiophene ring with a bromomethyl group at the 2-position and a nitro group at the 5-position. It is commonly used in organic synthesis and medicinal chemistry as a building block for the development of various pharmaceutical compounds. This chemical is known for its reactivity as a bromomethylating agent, meaning it can add a bromomethyl group to other molecules in a chemical reaction. It is important to handle this compound with caution due to its potential hazards and toxicity. Additionally, its chemical properties make it useful for a wide range of applications in research and development.

Upstream product

• 20898-85-5 (5-nitrothiophen-2-yl)methanol 
• 4521-33-9 5-nitro-2-thiophenecarboxaldehyde 
• 558-13-4 carbon tetrabromide 
• 42297-94-9 5-nitro-2-methylthiophene 

Downstream Products

• 82118-18-1 (5-nitrofuran-2-yl)methyl carbamimidothioate hydrobromide 

Relevant articles and documents

Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor

Tumor hypoxia is associated with therapy resistance and poor patient prognosis. Hypoxia-activated prodrugs, designed to selectively target hypoxic cells while sparing normal tissue, represent a promising treatment strategy. We report the pre-clinical efficacy of 1-methyl-2-nitroimidazole panobinostat (NI-Pano, CH-03), a novel bioreductive version of the clinically used lysine deacetylase inhibitor, panobinostat. NI-Pano was stable in normoxic (21% O2) conditions and underwent NADPH-CYP-mediated enzymatic bioreduction to release panobinostat in hypoxia (2). Treatment of cells grown in both 2D and 3D with NI-Pano increased acetylation of histone H3 at lysine 9, induced apoptosis, and decreased clonogenic survival. Importantly, NI-Pano exhibited growth delay effects as a single agent in tumor xenografts. Pharmacokinetic analysis confirmed the presence of sub-micromolar concentrations of panobinostat in hypoxic mouse xenografts, but not in circulating plasma or kidneys. Together, our pre-clinical results provide a strong mechanistic rationale for the clinical development of NI-Pano for selective targeting of hypoxic tumors.

7-((5-Nitrothiophen-2-yl)methoxy)-3H-phenoxazin-3-one as a spectroscopic off-on probe for highly sensitive and selective detection of nitroreductase

A new spectroscopic off-on probe, 7-((5-nitrothiophen-2-yl)methoxy)-3H- phenoxazin-3-one, is developed and applied to real-time detection of nitroreductase produced by Escherichia coli.

Expanding the donor-acceptor toolbox with a minimal 5-(thiophen-2-yl)-1,3-thiazole core: Transition metal-free synthesis and molecular design for HOMO-LUMO energy modulations

Synthesis of a minimal 5-(thiophen-2-yl)-1,3-thiazole core through a transition metal-free, versatile [4+1] route is reported. DFT calculations on a prototype library of D-A-D-A tetrads established the exquisite HOMO-LUMO energy modulation by varying peri